ArticleTechnology in cancer research & treatment
Effect of Cisplatin Cycles on Prognosis for Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy: A Retrospective Cohort Study.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionTo assess the impact of cisplatin cycles on overall survival (OS) and disease-free survival (DFS) in cervical cancer (CC) patients undergoing concurrent chemoradiotherapy (CCRT), and to build a nomogram-based prognostic stratification to identify CC patients who might benefit from ≥ 5 cycles of cisplatin.MethodsThis study retrospectively analyzed data from 918 patients who were treated with external beam radiotherapy and brachytherapy. Weekly cisplatin was the concurrent regimen. The difference in survival outcomes between the < 5 cycles and ≥ 5 cycles groups were compared. Subgroup analysis was further conducted. Univariate and multivariate Cox regression analyses were performed in the <5 cycles, and a nomogram was developed accordingly. The patients were divided into two risk subgroups and the survival outcomes were compared.ResultsThe 5-year OS and DFS were 76.7% and 86.1% (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.